Oncology Institute (NASDAQ:TOI) Shares Up 6.5% Following Analyst Upgrade

Posted by Geri Gentry on Jun 17th, 2026

The Oncology Institute, Inc. (NASDAQ:TOI – Get Free Report) traded up 6.5% during mid-day trading on Wednesday after Needham & Company LLC raised their price target on the stock from $5.00 to $7.00. Needham & Company LLC currently has a buy rating on the stock. Oncology Institute traded as high as $5.38 and last traded at $5.4340. 154,228 shares were traded during trading, a decline of 92% from the average session volume of 1,879,599 shares. The stock had previously closed at $5.10.

TOI has been the topic of a number of other research reports. BTIG Research raised their price objective on shares of Oncology Institute from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. Finally, B. Riley Financial upped their target price on Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Oncology Institute currently has an average rating of “Moderate Buy” and a consensus price target of $7.75.

Read Our Latest Analysis on Oncology Institute

Insider Activity

In other Oncology Institute news, insider Yale Podnos sold 23,451 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the transaction, the insider directly owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. This trade represents a 8.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mohit Kaushal sold 38,433 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $3.50, for a total transaction of $134,515.50. Following the completion of the sale, the director owned 172,583 shares in the company, valued at approximately $604,040.50. This trade represents a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have bought 250,500 shares of company stock worth $870,795 and have sold 119,170 shares worth $461,183. Insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

Large investors have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new stake in shares of Oncology Institute during the fourth quarter valued at $31,000. Pekin Hardy Strauss Inc. purchased a new position in Oncology Institute in the 4th quarter worth about $36,000. R Squared Ltd acquired a new stake in Oncology Institute during the 4th quarter worth about $41,000. Prelude Capital Management LLC purchased a new stake in Oncology Institute during the third quarter valued at about $41,000. Finally, BNP Paribas Financial Markets lifted its stake in Oncology Institute by 141.0% during the third quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock valued at $42,000 after buying an additional 7,091 shares in the last quarter. 36.86% of the stock is owned by institutional investors.

Oncology Institute Price Performance

The firm’s fifty day simple moving average is $4.07 and its 200 day simple moving average is $3.48. The company has a market capitalization of $534.23 million, a price-to-earnings ratio of -14.63 and a beta of 0.37.

Oncology Institute (NASDAQ:TOI – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.05. The firm had revenue of $147.44 million during the quarter, compared to analysts’ expectations of $142.10 million. Equities research analysts forecast that The Oncology Institute, Inc. will post -0.17 earnings per share for the current fiscal year.

About Oncology Institute

(Get Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.